Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lung Therapeutics closes $14.3mm Series B

Executive Summary

Respiratory disease-focused Lung Therapeutics Inc. raised $14.3mm in its Series B financing led by Bios Partners, which was joined by returning shareholder the UT Horizon Fund. The company will use the funds for ongoing clinical trials in Australia and New Zealand of its LTI01 for empyema and complicated parapneumonic effusions, and for continued development of preclinical LTI03 for idiopathic pulmonary fibrosis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies